Expands company’s patent portfolio in pursuit of worldwide intellectual property protection for proprietary technology that detects biomarkers in tissue, blood, and cerebrospinal fluid SAN DIEGO --(BUSINESS WIRE)--Jul. 6, 2021-- Biocept, Inc . (NASDAQ: BIOC), a leading provider of molecular
SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it has received more than 420,000 samples for SARS-CoV-2 testing since launching this service in June 2020 .
Further expands global patent estate for capturing and detecting rare cells of interest, including CTCs, to aid in the treatment of patients with cancer SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products
Intellectual property estate now includes 25 issued patents for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs) SAN DIEGO , Feb. 5, 2018 /PRNewswire/ -- Biocept, Inc.
Announces distribution of nearly 12,000 specimen collection kits to clients and has current availability of approximately 18,000 kits for immediate distribution Expects Company-developed collection kits to be available later this quarter SAN DIEGO , Aug. 3, 2020 /PRNewswire/ -- Biocept, Inc .
Biocept Publishes on Mechanics and Performance of its Onco CEE™ Platform for Circulating Tumor Cells (CTCs) in Cancer Patients San Diego, California: – Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs)
SAN DIEGO , Oct. 29, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 80,000 samples received to date for processing
SAN DIEGO , Oct. 6, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces it has received more than 50,000 COVID-19 specimens to date for processing through its RT-PCR
SAN DIEGO --(BUSINESS WIRE)--Apr. 14, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020 , it has now received more than 350,000 samples for testing.
SAN DIEGO --(BUSINESS WIRE)--Feb. 3, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, provides an update on its COVID-19 testing with more than 250,000 samples received to date for processing
